Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PENTIDS 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PENTIDS 400.
OMNIPEN (AMPICILLIN) vs PENTIDS '400'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
400 mg orally every 6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
0.5-1 hour in patients with normal renal function. Prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Primarily renal (tubular secretion and glomerular filtration); 60-90% of dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<10%) and fecal elimination.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic